News | November 04, 2023
Henkel launches new medical grade wearables device light cure adhesives
The newly developed adhesive is available in two different grades. Loctite WT 3001 and Loctite WT 3003 h
The newly developed adhesive is available in two different grades. Loctite WT 3001 and Loctite WT 3003 h
Impressive safety and efficacy for solid cancer patients followed by global clinical study plan
The companies plan to start a pivotal Phase 3 trial in the coming months
Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients
The sBLA is supported by a usability study which confirmed that individuals over 18 years of age could self-administer
The company expects that this development could improve the strength of its application to the FDA for new drug approval
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
CB03 is a candidate drug for the treatment of ALS and other central nerve system (CNS) diseases
LG Chem is making progress in the development of the world's first oral treatment for rare forms of obesity.
The vaccine further advances Pfizer’s vaccine portfolio and builds on more than 20 years of expertise and knowledge in the prevention of meningococcal disease
Subscribe To Our Newsletter & Stay Updated
